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Breast cancer brain metastases: the last 
frontier
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Abstract 
Breast cancer is a common cause of brain metastases, with metastases occurring in at least 10–16 % of patients. 
Longer survival of patients with metastatic breast cancer and the use of better imaging techniques are associated 
with an increased incidence of brain metastases. Unfortunately, patients who develop brain metastases tend to have 
poor prognosis with short overall survival. In addition, brain metastases are a major cause of morbidity, associated 
with progressive neurologic deficits that result in a reduced quality of life. Tumor subtypes play a key role in prognosis 
and treatment selection. Current therapies include surgery, whole-brain radiation therapy, stereotactic radiosurgery, 
chemotherapy and targeted therapies. However, the timing and appropriate use of these therapies is controversial 
and careful patient selection by using available prognostic tools is extremely important. This review will focus on cur-
rent treatment options, novel therapies, future approaches and ongoing clinical trials for patients with breast cancer 
brain metastases.
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Background
Breast cancer represents the second most frequent 
cause of brain metastases after lung cancer, with metas-
tases occurring in 10–16  % of patients [1]. In addition, 
autopsy studies have demonstrated another 10  % which 
were asymptomatic [2]. The incidence of brain metasta-
ses seem to have increased in recent years, this is likely 
due to prolonged survival of patients receiving more 
efficient treatments and the availability of better imag-
ing techniques that lead to increased detection of brain 
metastases.
The development of brain metastases is a complex pro-
cess, requiring invasion of the primary breast cancer cells 
into surrounding tissue and vessels, traffic through the 
circulatory system and colonization and growth in the 
brain parenchyma [3, 4]. In breast cancer, this process 
takes a median of 32 months from the initial cancer diag-
nosis [5]; which shows that the breast cancer tumor cells, 
unlike other cancer cells, need more time to develop 
the ability to penetrate through the blood–brain bar-
rier (BBB) and colonize the brain. There is also a selec-
tive pressure that can make the brain a preferential site of 
metastasis, as many of our currently available therapies 
are unable to cross the BBB, even if this barrier is dis-
rupted by tumor invasion.
Previous studies have identified the subgroups of 
patients with triple-negative and human epidermal 
growth factor receptor 2 (HER2)-positive breast can-
cer as having an increased risk for the development of 
brain metastases [6–9], with up to half of patients with 
HER2-positive metastatic breast cancer experiencing 
brain metastases over time [10]. Tumor subtypes are also 
an important factor for the median time interval from 
primary diagnosis to development of brain metastases; 
a recent large study showed shorter intervals for triple-
negative and HER2-positive patients, and longer intervals 
for estrogen receptor (ER) positive tumors [11].
Brain metastases in breast cancer patients represent a 
catastrophic event that portends a poor prognosis, with 
a median survival that ranges from 2 to 25.3  months 
despite treatment [5, 12–14]. In addition, brain metas-
tases are a major cause of morbidity, associated with 
progressive neurologic deficits that result in a reduced 
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quality of life [15]. With the advent of better systemic 
therapies, brain metastases constitute an increasing clini-
cal problem. This is particularly important in HER2-pos-
itive patients, in whom brain metastases can occur in the 
setting of controlled extracranial disease [16]. In contrast, 
it is common for patients with triple-negative breast can-
cer to develop brain metastases with concurrent extrac-
ranial disease progression [17]. Treatment options for 
patients with breast cancer brain metastases are limited 
and include surgical resection, whole-brain radiation 
therapy (WBRT), stereotactic radiosurgery (SRS), chem-
otherapy and targeted therapy [12, 18, 19]. This review 
will focus on the key issues of current treatment options, 
comment on novel therapies and ongoing clinical trials 
for patients with breast cancer brain metastases.
Prognostic factors
The prognosis of patients with breast cancer who develop 
brain metastases is affected by several factors. Tumor 
subtypes have been identified as a prognostic factor 
for overall survival in brain metastases [20, 21]. Triple-
negative breast cancer patients have the shortest sur-
vival ranging from 3 to 4 months [9, 16, 22]. In contrast, 
patients with HER2-positive tumors have longer survival 
than those with triple-negative or luminal subtypes, 
although their rates of brain metastases are higher [9, 16, 
23].
Another important prognostic factor is the perfor-
mance status of the patient at the time of diagnosis of 
brain metastases. Most studies have established the util-
ity of the Karnofsky Performance Status (KPS) as a tool to 
assess prognosis and identified that patients with longer 
survival have KPS scores ≥70 [13, 14, 24]. In addition to 
the KPS, patient’s age can also affect prognosis. Older 
age at the time of initial breast cancer diagnosis has been 
associated with shorter overall survival and shorter sur-
vival from the time of first tumor relapse [5, 25]. Finally, 
the burden of disease represented by the number of 
brain metastases, as well as the presence of uncontrolled 
extracranial disease have both been related with worse 
prognosis [23, 24, 26].
One of the most frequently used tools for the assess-
ment of prognosis in brain metastases is the graded 
prognostic assessment (GPA) [27]. This prognostic index 
includes age, KPS score, number of brain metastases and 
extracranial metastases. After its original validation [28], 
the index was modified to create a breast cancer-specific 
GPA that included tumor subtypes among its prognostic 
factors [11, 14]. However, number of brain metastases 
was not incorporated into the final model. A recent study 
validated the breast cancer-specific GPA and refined it 
with the addition of number of brain metastases [29]. 
This represents a very useful tool for patient risk assess-
ment and selection for clinical trials.
Local therapy modalities
Surgical resection
Surgical resection of the brain metastasis is an impor-
tant treatment option in patients with single or few (≤3) 
lesions. Particularly when the systemic disease is well 
controlled and when the brain metastases are sympto-
matic. Although the anatomic location of the metastatic 
lesion can be a limitation, surgical resection has addi-
tional advantages including the potential for immediate 
improvement of focal deficits, relief of intracranial hyper-
tension and establishment of histological diagnosis in 
patients with no other site of metastasis.
One of the first studies to evaluate the role of sur-
gical resection in brain metastasis was conducted by 
Patchell et  al. [30]. In this study, 48 patients with single 
brain metastasis from any primary were randomized 
to either surgical resection of the brain metastasis fol-
lowed by WBRT or needle biopsy followed by WBRT. 
Brain recurrence was less frequent in the surgery group 
compared with the radiation group (20 vs. 52 %, respec-
tively; P < 0.02). Median overall survival was longer in the 
surgery group (40  weeks) compared with the radiation 
group (15 weeks) (P < 0.01). Neurological outcomes were 
also improved with surgery where patients remained 
functionally independent longer (median, 38 vs. 8 weeks 
in the radiation group; P < 0.005).
A subsequent study randomized 63 patients with sys-
temic cancer and a single brain metastasis to surgical 
resection plus WBRT vs. WBRT alone. The combined 
modality led to longer overall survival and longer func-
tionally independent survival compared with WBRT 
alone, particularly in patients with stable extracranial 
disease (median overall survival 12 vs. 7 months, respec-
tively; median functionally independent survival 9 vs. 
4  months, respectively) [31]. Patients with progressive 
extracranial disease had similar outcomes irrespective 
of treatment, a finding that was also observed in another 
randomized trial [32]. Three non-randomized stud-
ies have also confirmed improvements in survival, brain 
recurrence and neurological outcomes with surgical 
resection in addition to WBRT [33–35].
Stereotactic radiosurgery
In patients with limited brain metastases who are deemed 
poor candidates for surgical resection or who have 
lesions in difficult anatomic locations, SRS has been pro-
posed as an alternative treatment option. This approach 
delivers a high-precision photon radiation to a small tar-
get volume while sparing most normal brain tissues. SRS 
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has an advantage over WBRT in that it avoids the feared 
toxicity of neurocognitive decline that is associated with 
the latter intervention [36–38].
The efficacy of SRS for local control of brain metas-
tases has been demonstrated in a study conducted by 
Kondziolka et al. [36], were median time to local failure 
in patients with two to four brain metastases was sig-
nificantly improved from 6 months with WBRT alone to 
36 months with the addition of SRS (P = 0.0005). In spite 
of this improvement in local control, overall survival was 
unchanged and was related to the extent of extracranial 
disease. The Radiation Therapy Oncology Group (RTOG) 
confirmed the efficacy of SRS in addition to WBRT in 
patients with one to three brain metastases and docu-
mented an overall survival improvement of 1.6  months 
in the subgroup of patients with single unresectable brain 
metastasis who received the combined therapy [39]. In 
patients with solitary metastases who are treated with 
surgical resection plus WBRT, the addition of SRS to the 
tumor bed can improve local control [40].
Subsequent randomized studies that included brain 
metastases from different cancers demonstrated that 
patients with one to four lesions who were treated with 
SRS alone had similar survival and improved neurocog-
nition compared with patients who received both SRS 
and WBRT, however local control was inferior with SRS 
alone [41, 42]. These results were confirmed in a meta-
analysis [43]. A recent non-randomized non-inferiority 
trial showed the efficacy of SRS without WBRT for over-
all survival in patients with five to ten brain metastases to 
be not inferior to the same treatment in patients with two 
to four lesions [44]. Despite the findings of this study and 
others showing similar clinical outcomes [45–47], cur-
rently there is no randomized data to support the use of 
SRS without WBRT in the treatment of brain metastases 
for patients with >4 lesions.
Whole‑brain radiation therapy
One of the most important treatments available for brain 
metastases is WBRT, particularly in the setting of multi-
ple brain lesions. This approach has two main goals—the 
control of macroscopic metastases, and the eradication of 
microscopic seeding of the brain. The majority of patients 
are given conventional WBRT, a total dose of 30 Gy in 10 
fractions with daily fractions of 3–4 Gy [48].
The benefit of WBRT after surgical resection has been 
demonstrated in a prospective trial that randomized 95 
patients who had single brain metastases to WBRT or 
observation [49]. The study showed that patients in the 
WBRT group had fewer recurrences both at the operative 
site (10 vs. 46 %, P < 0.001) and at other sites in the brain 
(14 vs. 37 %, P < 0.01), however overall survival was not 
increased.
Substantial controversy exists about the role of WBRT 
in patients with few (≤4) brain metastases. In this set-
ting, treatment with WBRT after surgical resection or 
SRS resulted in fewer intracranial recurrences, but there 
was no difference in overall survival [41, 50]. Associated 
toxicities with WBRT included worse neurocognitive 
outcomes and quality of life [42, 51]. However, withhold-
ing WBRT can lead to progressive disease in the brain, 
which in turn could also negatively impact cognition [52, 
53]. This issue was addressed in a study conducted by 
the North Central Cancer Treatment Group (NCCTG) 
N0574 where patients with one to three brain metastases 
were randomized to SRS or SRS plus WBRT, the study 
showed more frequent decline in cognitive function with 
the addition of WBRT despite better brain control [54]. 
Therefore, delaying or avoiding the administration of 
WBRT in metastatic breast cancer after surgical resec-
tion or SRS through the careful use of effective systemic 
therapies, could provide substantial benefits in terms 
of quality of life, particularly in patients with high GPA 
scores in whom survival is expected to be longer [14, 29]. 
This approach results even more appealing when one 
considers that none of the above mentioned randomized 
trials have shown overall survival gain with the addition 
of WBRT.
Systemic therapies
The mainstay of systemic treatment for breast cancer 
brain metastases is cytotoxic chemotherapy; however, 
there are currently additional options for targeted ther-
apy. Therefore, it is crucial to consider the tumor subtype 
not only for prognosis but also to understand the differ-
ent options for systemic therapies.
Hormone receptor‑positive
Patients with ER-positive brain metastases derive sub-
stantial benefit from systemic chemotherapy. Niwinska 
et  al. reported improvements in median survival from 
3 to 14 months with the addition of systemic therapy in 
patients with luminal breast cancer [20]. A similar result 
was seen in another study where the median overall sur-
vival of patients with luminal breast cancer was improved 
from 7.1 to 14.3 months with chemotherapy [55].
The efficacy of endocrine therapy for brain metas-
tases is less clear, since most randomized trials testing 
this intervention excluded these patients. Despite of 
this, there are some reports showing response of brain 
metastases to tamoxifen, megestrol acetate and aro-
matase inhibitors [56–61]. Interestingly, tamoxifen and 
its metabolites can achieve high concentrations in the 
brain. Lien et al. showed that the concentrations were up 
to 46-fold higher in the brain metastatic tumor and brain 
tissue than in serum [62]. Taken together, these data 
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support the hypothesis that in patients with metastatic 
ER-positive breast cancer who have asymptomatic sys-
temic disease and locally treated brain metastases treat-
ment with endocrine therapy could be considered prior 
to systemic chemotherapy. Clinical trials evaluating this 
approach should be conducted.
HER2‑positive
Patients with HER2-positive metastatic breast cancer 
have experienced a dramatic improvement in overall 
survival with optimal the utilization of HER2 targeted 
therapy [63]. Unfortunately, the advances in systemic 
treatments for these patients came in hand with an 
increase in the rate of brain metastases, which now 
poses a significant threat [10]. The efficacy of anti-HER2 
therapy to control systemic disease for longer periods of 
time has exposed the ability of the HER2-positive breast 
cancer cells to seed the brain parenchyma and develop 
brain metastases. Most chemotherapy agents and HER2 
targeted therapies do not cross the intact BBB or are 
pumped out of the central nervous system (CNS) by 
P-glycoproteins present in the BBB, therefore they may 
not reach sufficient therapeutic levels to eradicate met-
astatic cells [1]. For example, in patients without brain 
metastases, the ratio of trastuzumab in plasma to tras-
tuzumab in cerebrospinal fluid is >300:1 [64, 65]. The 
brain then, can serve as a sanctuary where those cells that 
have the ability to seed can escape the cytotoxic efficacy 
of systemic therapy. However, tumor growth in the brain 
as well as cranial surgery and brain radiotherapy can dis-
rupt the BBB and allow access of systemic drugs to the 
tumor. This concept has been proven by a number of 
labeled-trastuzumab imaging studies [66, 67]. Also, sev-
eral clinical studies have shown that the combination of 
chemotherapy with trastuzumab improved survival, even 
after the development of brain metastases [68–70]. This 
benefit is presumed to be mainly due to improved control 
of systemic disease [71].
Lapatinib, a small molecule with potential ability to 
cross the BBB, has been extensively tested in the treat-
ment of HER2-positive brain metastases. As a single 
agent, lapatinib has shown response rates in the brain 
ranging from 2.6 to 6  % in heavily pre-treated patients 
[72, 73]. However, when added to capecitabine, response 
rates increase to 20 to 33  % [73–77]. The highest effi-
cacy is observed in previously untreated patients, where 
the combination of lapatinib and capecitabine produces 
an objective response rate of 65.9  %, with a median 
time to progression of 5.5 months and a 1-year survival 
rate >70  % [78]. This drug combination has also shown 
to reduce the rate of brain metastases as the first site 
of progression from 6 % with capecitabine alone to 2 % 
with capecitabine and trastuzumab (P = 0.045) [79]. The 
efficacy of lapatinib to prevent brain metastases was fur-
ther tested in the CEREBEL trial, where patients with 
HER2-positive metastatic breast cancer without CNS 
metastases were randomized to lapatinib or trastuzumab 
in combination with capecitabine. The primary end point 
of the study was incidence of CNS metastases as first site 
of relapse. The study was terminated early and showed 
no difference between arms for the incidence of CNS 
metastases (3  % for lapatinib vs. 5  % for trastuzumab, 
P = 0.36), however progression-free survival and overall 
survival were longer with trastuzumab and capecitabine 
[80]. Despite the low incidence of CNS metastases seen 
during the study, it is important to notice that 4.7  % of 
all screened patients were excluded due to detection of 
asymptomatic brain metastases.
In the EMILIA trial, Trastuzumab emtansine (T-DM1), 
a novel antibody–drug conjugate, improved overall 
survival compared with lapatinib plus capecitabine in 
patients with previously treated HER2-positive meta-
static breast cancer [81]. A recent retrospective, explor-
atory analysis of this trial focusing on patients with 
baseline CNS metastases, showed that the rate of CNS 
progression was similar for both arms, however median 
overall survival in patients with CNS metastases at base-
line was significantly improved with T-DM1 (26.8 vs. 
12.9  months, P =  0.008) [82]. Similar results were seen 
in the CLEOPATRA trial, where patients with HER2-
positive first line metastatic breast cancer experienced 
significant improvements in progression-free and over-
all survival with pertuzumab, trastuzumab and docetaxel 
compared with placebo, trastuzumab and docetaxel [63]. 
In this trial, an exploratory analysis of the incidence 
and time to development of CNS metastases as first site 
of disease progression, also showed that the incidence 
was similar between the two arms, however the time to 
development of CNS metastases was significantly pro-
longed in the pertuzumab arm from 11.9 to 15  months 
(P = 0.0049) [83]. Taken together, the data from EMILIA 
and CLEOPATRA underscore the importance of sys-
temic disease control for improving overall survival in 
patients with brain metastases.
Given the high prevalence and impact that brain 
metastases cause in patients with HER2-positive breast 
cancer, the American Society of Clinical Oncology 
(ASCO) published in 2014 its first clinical practice guide-
line on the management of patients with HER2-positive 
brain metastases [84]. Some of the key recommenda-
tions included the following: (a) for patients with pro-
gressive intracranial metastases, options include a trial 
of systemic therapy in addition to other local therapy 
modalities; (b) for patients whose systemic disease is 
not progressive at the time of brain metastasis diagnosis, 
systemic therapy should not be changed; (c) for patients 
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whose systemic disease is progressive at the time of brain 
metastasis diagnosis, treatment should include HER2-
targeted therapy according to the algorithms for treat-
ment of HER2-positive metastatic breast cancer [85].
Triple‑negative
Patients with brain metastases from triple-negative 
breast cancer unfortunately lack targeted therapies and 
chemotherapy is currently their only systemic option.
Some of the initial studies of patients with brain metas-
tases have shown objective response rates of around 50 % 
with traditional chemotherapy combinations [86, 87]. A 
study evaluating cisplatin with etoposide showed 38  % 
response rate in the brain [88]. Topotecan and temozola-
mide have failed to show responses as single agent [89, 
90]. However, when temozolamide was combined with 
cisplatin had 40 % response rate [91], and showed 18 % 
response rate when combined with capecitabine [92]. 
The experience with single agent capecitabine is limited 
to mostly retrospective studies [93].
It is important to keep in mind that while different 
chemotherapies will defer in their ability to penetrate 
the BBB, most brain metastases will significantly disrupt 
this barrier. Therefore the ability to deliver systemic 
chemotherapy to the brain metastasis is not much dif-
ferent from the ability to deliver chemotherapy to that 
tumor anywhere else in the body. Hence, treatment 
efficacy is more closely related to tumor chemosen-
sitivity than to the drug ability to cross an intact BBB 
and this hypothesis has been proven in several of the 
above mentioned studies [86–88]. Brain metastases 
tend to be chemotherapy-resistant because they tend 
to occur late in the natural history of breast cancer and 
by that point many times the breast cancer is already 
chemotherapy-resistant.
Suggested treatment approach
Based on the evidence reviewed above, we suggest the 
following management approach:
a. For patients with a single brain metastasis, surgical 
resection can improve overall survival, particularly in 
symptomatic patients when systemic disease is well 
controlled. The addition of SRS to the tumor bed or 
WBRT improve local control.
b. For patients with one to four brain metastases, SRS 
with or without WBRT should be considered to 
improve local control. If WBRT is added, we recom-
mend to delay its administration as much as possible 
to prevent neurocognitive decline, which is particu-
larly important in the absence of overall survival ben-
efit. Surgery can be considered for large or sympto-
matic lesions.
c. For patients with more than four brain metastases, 
WBRT can be the treatment of choice to palliate 
symptoms and improve local control. There are no 
randomized trials to support the use of SRS in this 
setting.
d. For patients with progressive systemic disease at the 
time of development of brain metastases, a change in 
systemic therapy should be considered based on the 
tumor subtype.
e. For patients with non-progressive systemic disease 
at the time of development of brain metastases, sys-
temic therapy should not be changed.
f. For each patient, the choice of systemic therapy 
should be considered based on the tumor subtype.
g. For patients with poor prognosis, options include 
WBRT and/or best supportive care.
Novel approaches and future directions
Given the paucity of effective treatment options for 
patients with breast cancer brain metastases, this cur-
rently represents an area of great potential for future 
research. The use of bevacizumab has shown good results 
in patients with glioblastoma and has made the strat-
egy of blocking the vascular endothelial growth factor 
(VEGF) pathway an interesting alternative to treat brain 
metastases. Two studies evaluating this approach have 
been reported. One showed CNS response rate of 63 % 
for bevacizumab and carboplatin; and the other one 
showed a response rate of 60 % for bevacizumab, etopo-
side and cisplatin [94, 95]. It is important to consider that 
VEGF blockade rises a number of controversies. One of 
the most concerning being that meta-analyses have failed 
to show an overall survival benefit with the use of bevaci-
zumab in metastatic breast cancer, which resulted in the 
US Food and Drug Administration (FDA) withdrawal of 
the conditional approval of the drug.
The high affinity folate receptor (HFR) is a novel tar-
get present in 33  % of breast cancers for which there 
are available drugs being evaluated. Despite of the ini-
tial excitement, a recent study showed very low levels of 
expression in brain metastases [96]. Another approach 
that is currently under study in patients with breast can-
cer brain metastases is targeting the phosphatidylino-
sitol 3-kinase (PI3K)—mammalian target of rapamycin 
(mTOR) pathway. This is one of the most commonly 
altered pathways not only in metastatic breast cancer 
but also in brain metastases [97]. Everolimus is being 
evaluated in combination with capecitabine and lapatinib 
(NCT01783756) and in combination with vinorelbine 
and trastuzumab (NCT01305941) in patients with HER2-
positive brain metastases.
Given the high incidence of brain metastases, particularly 
for patients with HER2-positive and triple-negative breast 
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cancer, there have been efforts to develop strategies for 
prevention of brain metastases in the high-risk subgroups. 
Much of these have evolved around the concept of using 
prophylactic cranial irradiation (PCI) in patients with these 
breast cancer subtypes, similar to what is currently done 
for patients with small cell lung cancer. However, as men-
tioned earlier in this article, the timing of development of 
brain metastases in patients with HER2-positive and triple-
negative breast cancer is not the same, nor is the same their 
survival after development of metastatic disease. In addi-
tion, given the cognitive effects of brain radiotherapy, there 
is significant controversy around the optimal timing of PCI.
Table 1 shows a summary of currently ongoing studies 
evaluating different treatment strategies in breast cancer 
brain metastases.
Conclusions
Brain metastases are an increasing problem in breast 
cancer. They represent an unmet need for which more 
efficacious therapies are urgently required. A better 
understanding of the molecular underpinnings of CNS 
progression is needed and ongoing studies analyzing 
matched tissue from primary and brain metastases 
will hopefully shed light on this. Traditionally, patients 
with brain metastases were excluded from clinical tri-
als evaluating systemic therapies and we are left with 
the unanswered question of how efficacious those 
therapies would be for patients with brain metastases. 
To this end, the large number of ongoing breast can-
cer-specific brain metastases trials is a step in the right 
direction.
Table 1 Ongoing clinical trials in breast cancer brain metastases
Tumor subtype Treatment/ 
target
Experimental arm Control arm Clinicaltrials.gov ID/
phase
All Chemotherapy Cabazitaxel None NCT02166658
Phase II




ANG1005 + trastuzumab (if HER2-positive) None NCT01480583
Phase II
Liposomal cytarabine + high-dose methotrexate None NCT00992602
Phase II




Bevacizumab + etoposide + cisplatin followed by WBRT WBRT alone NCT02185352
Phase II
Sorafenib + WBRT None NCT01724606
Phase I
Cabozantinib + trastuzumab (if HER2-positive) None NCT02260531
Phase II
Radiation WBRT + temozolamide None NCT02133677
Phase II
WBRT with hippocampal avoidance Conventional WBRT NCT01942980
Phase III
WBRT + efaproxiral + oxygen WBRT + oxygen NCT00083304
Phase III
HER2-positive Chemotherapy Cabazitaxel + lapatinib None NCT01934894
Phase II
HER2 Lapatinib + WBRT WBRT alone NCT01622868
Phase II
Neratinib ± capecitabine None NCT01494662
Phase II
Afatinib ± vinorelbine Investigator’s choice NCT01441596
Phase II
T-DM1 + WBRT None NCT02135159
Phase I
ARRY-380 + trastuzumab None NCT01921335
Phase I
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